3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
33
Lymphoma, Follicular
19
Lymphoma, Non-Hodgkin
16
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma
10
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma, B-Cell
5
Recurrence
4
Neoplasms
3
Leukemia, Hairy Cell
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Tumor Lysis Syndrome
1
Solid Tumors
1
Solid Cancers
1
Oncology Patients Receiving Chemotherapy
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Prolymphocytic
1
Leukemia, Lymphoid
1
Leukemia, B-Cell
1
Leukemia
1
Disease
1
Colorectal Neoplasms
1
Chromosome 17 deletion
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Gemcitabine
74
Capecitabine
60
Paclitaxel
59
Fluorouracil
58
Oxaliplatin
57
Bevacizumab
51
Docetaxel
50
Leucovorin
48
Nivolumab
40
Cisplatin
40
Irinotecan
39
Carboplatin
37
Cetuximab
34
pembrolizumab
32
Radiosurgery
32
Trastuzumab
30
Radiotherapy
27
Everolimus
24
Sorafenib
23
Pemetrexed
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Ipilimumab
19
Cyclophosphamide
19
Panitumumab
18
Zoledronic Acid
17
Lapatinib
17
Erlotinib Hydrochloride
17
Prednisone
16
pazopanib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasm Metastasis
×
obinutuzumab
×
Clear all
NCT04880863
2025-03-03
NT-NAP-102-1
NeoTX Therapeutics Ltd.
Phase 2
Completed
38 enrolled
13 charts